CN101676301B - Antibody for inhibiting growth of colorectal carcinoma and its use in preparation of medicament and kit - Google Patents
Antibody for inhibiting growth of colorectal carcinoma and its use in preparation of medicament and kit Download PDFInfo
- Publication number
- CN101676301B CN101676301B CN2008102224177A CN200810222417A CN101676301B CN 101676301 B CN101676301 B CN 101676301B CN 2008102224177 A CN2008102224177 A CN 2008102224177A CN 200810222417 A CN200810222417 A CN 200810222417A CN 101676301 B CN101676301 B CN 101676301B
- Authority
- CN
- China
- Prior art keywords
- monoclonal antibody
- antibody
- cancer
- carcinoma
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 206010009944 Colon cancer Diseases 0.000 title claims abstract description 50
- 208000001333 Colorectal Neoplasms Diseases 0.000 title claims abstract description 42
- 201000010989 colorectal carcinoma Diseases 0.000 title claims abstract description 18
- 239000003814 drug Substances 0.000 title claims abstract description 15
- 238000002360 preparation method Methods 0.000 title claims abstract description 9
- 230000012010 growth Effects 0.000 title abstract description 6
- 230000002401 inhibitory effect Effects 0.000 title 1
- 238000011282 treatment Methods 0.000 claims abstract description 27
- 210000004408 hybridoma Anatomy 0.000 claims abstract description 14
- 238000012360 testing method Methods 0.000 claims description 10
- 230000028327 secretion Effects 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 abstract description 83
- 238000003745 diagnosis Methods 0.000 abstract description 21
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 abstract description 19
- 239000000427 antigen Substances 0.000 abstract description 18
- 102000036639 antigens Human genes 0.000 abstract description 18
- 108091007433 antigens Proteins 0.000 abstract description 18
- 201000011510 cancer Diseases 0.000 abstract description 18
- 208000029382 endometrium adenocarcinoma Diseases 0.000 abstract description 13
- 201000003908 endometrial adenocarcinoma Diseases 0.000 abstract description 12
- 125000003275 alpha amino acid group Chemical group 0.000 abstract description 8
- 210000004881 tumor cell Anatomy 0.000 abstract description 8
- 208000008443 pancreatic carcinoma Diseases 0.000 abstract description 7
- 230000003248 secreting effect Effects 0.000 abstract description 7
- 108060003951 Immunoglobulin Proteins 0.000 abstract description 3
- 102000018358 immunoglobulin Human genes 0.000 abstract description 3
- 238000012544 monitoring process Methods 0.000 abstract description 3
- 238000012216 screening Methods 0.000 abstract description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 abstract 1
- 206010052360 Colorectal adenocarcinoma Diseases 0.000 abstract 1
- 102000001621 Mucoproteins Human genes 0.000 abstract 1
- 108010093825 Mucoproteins Proteins 0.000 abstract 1
- 238000003384 imaging method Methods 0.000 abstract 1
- 230000009450 sialylation Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 41
- 210000001519 tissue Anatomy 0.000 description 33
- 238000005406 washing Methods 0.000 description 30
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 27
- 238000000034 method Methods 0.000 description 23
- 241000699666 Mus <mouse, genus> Species 0.000 description 21
- 102000004169 proteins and genes Human genes 0.000 description 20
- 108090000623 proteins and genes Proteins 0.000 description 20
- 238000006243 chemical reaction Methods 0.000 description 19
- 241001494479 Pecora Species 0.000 description 17
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 16
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 15
- 238000010790 dilution Methods 0.000 description 15
- 239000012895 dilution Substances 0.000 description 15
- 208000029742 colonic neoplasm Diseases 0.000 description 14
- 238000001514 detection method Methods 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- 206010003445 Ascites Diseases 0.000 description 13
- 206010038019 Rectal adenocarcinoma Diseases 0.000 description 13
- 201000001281 rectum adenocarcinoma Diseases 0.000 description 13
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 12
- 238000002835 absorbance Methods 0.000 description 11
- 239000000872 buffer Substances 0.000 description 11
- 239000011248 coating agent Substances 0.000 description 11
- 238000000576 coating method Methods 0.000 description 11
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 11
- 238000011534 incubation Methods 0.000 description 11
- 239000007788 liquid Substances 0.000 description 11
- 239000000463 material Substances 0.000 description 11
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 10
- 206010014759 Endometrial neoplasm Diseases 0.000 description 10
- 230000008859 change Effects 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 230000000890 antigenic effect Effects 0.000 description 9
- 239000003153 chemical reaction reagent Substances 0.000 description 9
- 230000004069 differentiation Effects 0.000 description 9
- 238000002347 injection Methods 0.000 description 9
- 239000007924 injection Substances 0.000 description 9
- 239000000120 Artificial Saliva Substances 0.000 description 8
- 201000003914 endometrial carcinoma Diseases 0.000 description 8
- 210000004907 gland Anatomy 0.000 description 8
- 108010028349 saliva Orthana Proteins 0.000 description 8
- 101150049307 EEF1A2 gene Proteins 0.000 description 7
- 238000011161 development Methods 0.000 description 7
- 230000018109 developmental process Effects 0.000 description 7
- 238000007789 sealing Methods 0.000 description 7
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 6
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 6
- 230000014509 gene expression Effects 0.000 description 6
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 230000004614 tumor growth Effects 0.000 description 6
- 108700043183 Bos taurus BSM1 Proteins 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 102000005348 Neuraminidase Human genes 0.000 description 5
- 108010006232 Neuraminidase Proteins 0.000 description 5
- 201000010897 colon adenocarcinoma Diseases 0.000 description 5
- 230000008878 coupling Effects 0.000 description 5
- 238000010168 coupling process Methods 0.000 description 5
- 238000005859 coupling reaction Methods 0.000 description 5
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 5
- 229910000397 disodium phosphate Inorganic materials 0.000 description 5
- 235000019800 disodium phosphate Nutrition 0.000 description 5
- 238000010828 elution Methods 0.000 description 5
- 230000002357 endometrial effect Effects 0.000 description 5
- 238000011010 flushing procedure Methods 0.000 description 5
- 238000012151 immunohistochemical method Methods 0.000 description 5
- 230000005012 migration Effects 0.000 description 5
- 238000013508 migration Methods 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 238000013207 serial dilution Methods 0.000 description 5
- 239000001488 sodium phosphate Substances 0.000 description 5
- 206010001167 Adenocarcinoma of colon Diseases 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 4
- 238000011091 antibody purification Methods 0.000 description 4
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 4
- 238000004040 coloring Methods 0.000 description 4
- 238000013399 early diagnosis Methods 0.000 description 4
- 238000001378 electrochemiluminescence detection Methods 0.000 description 4
- 238000001962 electrophoresis Methods 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 210000004923 pancreatic tissue Anatomy 0.000 description 4
- 230000000452 restraining effect Effects 0.000 description 4
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- 238000011725 BALB/c mouse Methods 0.000 description 3
- 244000050510 Cunninghamia lanceolata Species 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000699660 Mus musculus Species 0.000 description 3
- CWHJIJJSDGEHNS-MYLFLSLOSA-N Senegenin Chemical compound C1[C@H](O)[C@H](O)[C@@](C)(C(O)=O)[C@@H]2CC[C@@]3(C)C(CC[C@]4(CCC(C[C@H]44)(C)C)C(O)=O)=C4[C@@H](CCl)C[C@@H]3[C@]21C CWHJIJJSDGEHNS-MYLFLSLOSA-N 0.000 description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 244000309466 calf Species 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 210000000981 epithelium Anatomy 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 230000013595 glycosylation Effects 0.000 description 3
- 238000006206 glycosylation reaction Methods 0.000 description 3
- 238000011532 immunohistochemical staining Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000007689 inspection Methods 0.000 description 3
- 238000011580 nude mouse model Methods 0.000 description 3
- 201000002528 pancreatic cancer Diseases 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 210000003296 saliva Anatomy 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 201000000498 stomach carcinoma Diseases 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 239000009871 tenuigenin Substances 0.000 description 3
- CERZMXAJYMMUDR-QBTAGHCHSA-N 5-amino-3,5-dideoxy-D-glycero-D-galacto-non-2-ulopyranosonic acid Chemical compound N[C@@H]1[C@@H](O)CC(O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO CERZMXAJYMMUDR-QBTAGHCHSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 108010063954 Mucins Proteins 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 208000015634 Rectal Neoplasms Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 230000002494 anti-cea effect Effects 0.000 description 2
- 230000001174 ascending effect Effects 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- HRBKVYFZANMGRE-UHFFFAOYSA-N chlorpyrifos-methyl Chemical compound COP(=S)(OC)OC1=NC(Cl)=C(Cl)C=C1Cl HRBKVYFZANMGRE-UHFFFAOYSA-N 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 210000004696 endometrium Anatomy 0.000 description 2
- 210000005002 female reproductive tract Anatomy 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- CERZMXAJYMMUDR-UHFFFAOYSA-N neuraminic acid Natural products NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO CERZMXAJYMMUDR-UHFFFAOYSA-N 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical class OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 2
- 230000000505 pernicious effect Effects 0.000 description 2
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- -1 polyoxyethylene Polymers 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 206010038038 rectal cancer Diseases 0.000 description 2
- 201000001275 rectum cancer Diseases 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- UBDHSURDYAETAL-UHFFFAOYSA-N 8-aminonaphthalene-1,3,6-trisulfonic acid Chemical compound OS(=O)(=O)C1=CC(S(O)(=O)=O)=C2C(N)=CC(S(O)(=O)=O)=CC2=C1 UBDHSURDYAETAL-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 238000011729 BALB/c nude mouse Methods 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 206010021703 Indifference Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 101100118097 Mus musculus Eef1a2 gene Proteins 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 208000033781 Thyroid carcinoma Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000012930 cell culture fluid Substances 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- YRQNKMKHABXEJZ-UVQQGXFZSA-N chembl176323 Chemical compound C1C[C@]2(C)[C@@]3(C)CC(N=C4C[C@]5(C)CCC6[C@]7(C)CC[C@@H]([C@]7(CC[C@]6(C)[C@@]5(C)CC4=N4)C)CCCCCCCC)=C4C[C@]3(C)CCC2[C@]2(C)CC[C@H](CCCCCCCC)[C@]21C YRQNKMKHABXEJZ-UVQQGXFZSA-N 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000009668 clonal growth Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000013016 damping Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 201000005619 esophageal carcinoma Diseases 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- 238000002594 fluoroscopy Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 210000003736 gastrointestinal content Anatomy 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002991 immunohistochemical analysis Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 238000011248 postoperative chemotherapy Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000011896 sensitive detection Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 201000008261 skin carcinoma Diseases 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- QTENRWWVYAAPBI-YCRXJPFRSA-N streptomycin sulfate Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O QTENRWWVYAAPBI-YCRXJPFRSA-N 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 208000013077 thyroid gland carcinoma Diseases 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 239000000439 tumor marker Substances 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Images
Abstract
The invention provides a monoclonal antibody, which has the following characteristics: 1) the antibody is IgMs immunoglobulin and the light-chain type of the antibody is K-typed; (2) the antigen is identified into a sugar-chain structure with sialylation mucoprotein surface; the monoclonal antibody can specifically identify colorectal adenocarcinoma, endometrial adenocarcinoma and pancreatic carcinoma tissues, can not identify the corresponding normal tissues. Specifically, the monoclonal antibody is formed by the secreting of hybridomas cells with the accession number of CGMCC No. 2643, the amino acid sequence in the heavy-chain variable zone is shown as SEQ ID NO: 1, the amino acid sequence in the light-chain variable zone is shown as SEQ ID NO: 2. The invention also provides a use of the monoclonal antibody in the preparation of a medicament or a kit, wherein the medicament or the kit can be used for the screening of cancer, early-stage diagnosis, treatment monitoring and tumour imaging. In addition, the invention provides a new antibody for inhibitting the growth of the tumor cells of colorectal carcinoma.
Description
Technical field
The invention belongs to the biological medicine technology field, particularly the invention provides specific recognition knot rectal adenocarcinoma, adenocarcinoma of endometrium and pancreatic cancer cell carbohydrate antigen, and can suppress the monoclonal antibody of colon tumor cell growth and secrete the hybridoma of this antibody, and described antibody is used for the treatment of the medicine of colon tumor and the application in the test kit in preparation, the present invention also provides medicine and test kit, and it comprises described monoclonal antibody as activeconstituents.
Background technology
Colorectal cancer refers to the pernicious change of large intestine intimal epithelium cell, comprises unusual differentiation, abnormality proliferation and cellular metabolism and diacrisis etc.The overwhelming majority of colorectal cancer (＞95%) is a gland cancer clinically, and the colorectal cancer of other type seldom comprises lymphoma, innocent tumor, pernicious sarcoma etc.The occurrence cause of knot rectal adenocarcinoma, diagnoses and treatment and prevention are preclinical medicine and clinical medical research emphasis always.
The mortality ratio of colorectal cancer occupies second of tumor mortality.The case that the U.S. is diagnosed as colorectal cancer every year surpasses 130,000, and is dead greater than 50,000, mortality ratio about 40%.Colorectal cancer is the 3rd a common digestive tract tumor in China, be positioned at after the esophageal carcinoma and the cancer of the stomach, but the annual case of dying from colorectal cancer is estimated to account for tumour 5.8% above 40,000 people.China's evident characteristic of colorectal cancer morbidity is the average age of onset one's mid-40s, shifts to an earlier date 12-18 than states such as America and Europes, and wherein the rectum cancer is more, accounts for 60%.Recent two decades, along with the progressively raising of Economic Growth in China and people's living standard, the number of the infected of China's colorectal cancer increases year by year, and morbidity more is tending towards rejuvenation.Clinical study is for many years found, if can early discovery diagnose with accurate, nearly all colorectal cancer can both be treated (Sanduleanu and Stockbrugger, 2003) to a certain extent, and therefore effective clinical means is to reducing the dead significant of colorectal cancer.
Carcinoma of the pancreas is the high digestive tract tumor of grade malignancy, and its mortality ratio accounts for the 6th of China's malignant tumour, is positioned at the 4th in the U.S..In recent years, the sickness rate of carcinoma of the pancreas is in rising trend, and five year survival rate is still very low, and the median survival interval after diagnosis is 4～6 months (Coppola, 2000).Carcinoma of the pancreas is because of its unique anatomical position, and symptom concealment, early diagnosis are very difficult, still do not have effective method of early diagnosis at present.At present, be used for clinical tumour antigen and detect, be nonspecific tumor associated antigen, can only carry out joint-detection, improve the susceptibility and the validity of detection by selecting suitable tumor markers.
Carcinoma of endometrium is the malignant tumour that betides endometrial one group of epithelium, claims carcinoma of uterine body again.The most common with the gland cancer that derives from endometrial gland, be called adenocarcinoma of endometrium.Carcinoma of endometrium is the female genital tract common cancer, and sickness rate accounts for female genital tract malignant tumour 20%～30%, and is continuous ascendant trend, accounts for women's general tumour 7%.In the treatment of Endometrial Carcinomas, operation is treated as first-selection and is accepted by world wide; Postoperative chemotherapy comes into one's own gradually; But its early stage diagnosis and treatment still are current subject matter.Traditional diagnostic method is according to clinical manifestation, and auxiliary examination is analysis-by-synthesis as a result, can make a definite diagnosis as the inspection that internal film tissue is learned.
Glycosylated change is the universals of cancer cells, and has the sugar chain structure of some types to be acknowledged as the mark that tumour takes place, develops, and specific tumor markers is detected purpose (Ho et al., 1988 that can reach the early diagnosis tumour; Kim, 1990; Kim, 1998a).Digestive tube intimal epithelium cell often causes when cancerating that glycosylation changes, and one of main change is the overexpression of Saliva Orthana (Mucin) in tumour, and another change is mucinous incomplete glycosylation.Existing research data shows that the incomplete glycosylated result of tumour cell produces Tn, T and sialic acid Tn (S-Tn) antigen, these antigenic structures under normal circumstances rarely found (Boland et al., 1986; Itzkowitz et al., 1989; Bresalier et al., 1991; Itzkowitz et al., 1992; Kim, 1998b; Hara et al., 2000).Although the pathological effect mechanism of the sugar chain of glycosylation and change in tumour generation and evolution is not clear, but TS sugar chain structure has become the marker of tumor monitoring, be used to find the early stage change of tumour, tumor development and prognosis, the oncotherapy effect assessment, even can become the target of oncotherapy.
Although detecting of colorectal cancer is very not difficult, at present for the diagnosis of colorectal carcinoma method of different times differ (Zhang et al., 2002; Winawer, 2005).Traditional inspection method has the intestines mirror, barivm meal fluoroscopy (screem) and intestinal contents detection etc., and diagnosis often relies on the clinician according to check result, the deduction of making in conjunction with practical experience.And for the infantile tumour that is confined to mucous membrane, traditional detection method is difficult to make accurately to be judged, need the sensitive detection means, set up multiple now in the molecular level detection technique, as RT-PCR, dna probe detects and special method (Finkelstein et al., 1996a such as tumour cell markers tests; Finkelstein et al., 1996b; Hammel and Soussi, 2000; Lassmann et al., 2002), can carry out early diagnosis to colorectal cancer delicately.Yet sensitive molecular detection technology RT-PCR, dna probe detect but and to hang down in clinical application lessly because of specificity, and in-vitro diagnosis mainly is the detection that relies on the kinds of tumors marker at present, and Comprehensive analysis results is judged again.
The diagnosis of colorectal cancer at present still adopts traditional inspection method to determine in conjunction with clinical symptom, to be existing tumor marker antibody exist factors such as poor specificity and identification antigen is uncertain to the identification of tumour to major cause, cause the susceptibility and the specificity low (Qin Xiaoguang, 1995) that detect colorectal cancer.In most bibliographical information, monoclonal antibody is respectively 30-60% and 20-50% to the susceptibility and the specificity of colorectal cancer.CEA, CA19-9, antigenic monoclonal antibody such as CA72-4 is to the auxiliary diagnosis of colorectal cancer, as anti-CEA monoclonal antibody identification carcinomebryonic antigen, because most of tumours are in various degree expression CEA all, so anti-CEA monoclonal antibody is used to diagnose the poor specificity of a certain tumour.But for improving the recall rate of colorectal cancer, multiple clinically monoclonal antibody coupling can improve and detects positive rate and see Table 1, becomes selection (Wu Daohong, 2004 of diagnosing tumour thus; Xu Xiaohong, 1998).
Table 1 CA-724, CA19-9, CEA and the positive findings of CA-50 to different tumours
At present, the diagnosis of carcinoma of the pancreas mainly realizes by the joint-detection of some tumor markerses commonly used, as CA19-9, and CA50, indexs such as CA242, they take place for diagnosing tumour, and vital role has been played in monitoring prognosis and recurrence.At present the most frequently used is with CEA, CA19-9 and CA242 coupling.The susceptibility of CA19-9 in carcinoma of the pancreas the strongest (80%), but specificity very low (43%) can be increased to 92% with specificity after CEA and the CA242 coupling, but after three's coupling, sensitivity only is 29% (Ni et al., 2005).The specificity of these indexs and susceptibility still can not meet clinical needs, and therefore need to seek new diagnosis and unite the early diagnostic rate that diagnosis index further improves carcinoma of the pancreas.
In recent years, in the diagnosis of Endometrial Carcinomas, sugar antigen becomes development rapidly, widely used tumor markers, be mainly glycoprotein and glycolipid, antigenic determinant is positioned on sugar chain or the pyrenoids, and their diagnosis that appears as clinical tumor brings convenience, as CA19-9, CA72-4, CA125, (Yamazawa et al., 2005 such as CA15-3; Hareyama et al., 1996; Cherchi et al., 2002; Lo et al., 1999).The susceptibility of these sugar antigens is all between 30%～67%.CA19-9 and CA125 coupling, susceptibility can be up to 83.3%, and specificity is 87.2%, and visible joint-detection can effectively improve correct diagnosis, and the auxiliary diagnosis of carcinoma of endometrium is had certain value.
In decades, monoclonal antibody plays a significant role in the diagnosis of disease and treatment, and particularly at the antigenic disease of expression specificity, monoclonal antibody and antigenic reaction detection can be used as " gold " standard of medical diagnosis on disease.But, different with other non-intestinal canal tumours is, colorectal cancer usually excessive secretion is expressed the glycosylated Saliva Orthana of surface elevation, cover Saliva Orthana owing to form " sugar quilt ", the monoclonal antibody of recognition protein epitope is subjected to sterically hindered the influence, can not effectively bring into play keying action, thereby use is little in diagnosis, on the contrary, can discern, become the important tool of diagnosis and treatment colorectal cancer in conjunction with the monoclonal antibody of mucin carbohydrate.
Monoclonal antibody called after 3P9 provided by the invention, through detecting the selective binding of monoclonal antibody to colon cancer cell, and with normal colon cell debond characteristic, multi-turns screen obtains.Different with present clinical application IgG antibody-like, 3P9 is an IgM class monoclonal antibody, therefore has antibody structure, biochemical characteristic and the biological function that is different from IgG.Our 3P9 monoclonal antibody molecule amount that experiment showed, is greater than 600KD, identification, is the s-Tn structure in conjunction with target epitope, and the specific recognition colorectal cancer born of the same parents that attenuate can suppress the migration of colon cancer cell and cause the colon cancer cell apoptosis.The immunohistochemical staining of this antibody of use can be diagnosed the colorectal cancer of various differentiation degrees comparatively exactly separately, carcinoma of endometrium, the canceration degree of carcinoma of the pancreas is determined cancerous region, changes to use this type of cancer susceptibility of multiple antibody combined diagnosis and/or the low present situation of specificity at present.The 3P9 monoclonal antibody suppresses the colon tumor growth and causes apoptotic function, demonstrates 3P9 monoclonal antibody potential using value aspect the treatment of adenocarcinoma of colon.
Summary of the invention
The purpose of this invention is to provide a kind of monoclonal antibody, described monoclonal antibody can combine with the cancer antigen specificity, thereby can be used to prepare the medicine or the test kit for the treatment of cancer.
Particularly, the invention provides following:
1. monoclonal antibody, described antibody has following feature: 1) antibody is the IgM immunoglobulin like protein, light chain of antibody type κ type; 2) identification antigen is Saliva Orthana surface saliva acidifying sugar chain structure.In one embodiment, described saliva acidifying sugar chain structure is s-Tn (sialic acid N-acetylglactoside) sugar chain structure.
2. above 1 described monoclonal antibody, its specific recognition knot rectal adenocarcinoma, adenocarcinoma of endometrium and carcinoma of the pancreas tissue, the corresponding healthy tissues of nonrecognition.
3. above 1 described monoclonal antibody, it is the hybridoma cell line secretion of CGMCC No.2643 by deposit number.
4. above 1 described monoclonal antibody, its weight chain variable region amino acid sequence as its light-chain amino acid sequence as shown in the SEQ ID NO:1 as shown in the SEQ ID NO:2.
5. genetic engineering antibody, itself and above or 4 described monoclonal antibodies have 30% above homologous sequence, comprising the Fab fragment, F (ab) ' fragment, the Fd fragment, Fv fragment and Fc fragment comprise that also each fragment with homologous sequence makes up mutually, or utilize part to have the derivative of each fragment of homologous sequence and other albumen, peptide chain formation.
One kind the coding above each described monoclonal antibody of 1-5 nucleotide sequence.
7. any one described monoclonal antibody is used for the treatment of the medicine of tumour or the application in the test kit in preparation in above 1 to 5.
8. above 7 described application, wherein said tumour are selected from the group of being made up of the tumour of expressing the sialic acid sugar chain structure.In one embodiment, described tumour is selected from by carcinoma of endometrium, colorectal cancer, carcinoma of the pancreas, ovarian cancer, spermary cancer, cancer of the stomach, the group that lung cancer and mammary cancer are formed.
9. medicine, it is used for the treatment of tumour, comprises each described monoclonal antibody of above 1-5 as activeconstituents.In one embodiment, described tumour is carcinoma of the pancreas, carcinoma of endometrium and colorectal carcinoma.
10. test kit, it is used for the treatment of tumour, comprises each described monoclonal antibody of above 1-5.In one embodiment, described tumour is carcinoma of the pancreas, carcinoma of endometrium and colorectal carcinoma.
The present invention's human colon cancer cell is an antigen, express the hybridoma cell strain (CGMCC No.2643) of IgM antibody-like by immune mouse acquisition-plant height, by identifying, determine the glycosylated sugar chain structure of antibody capable specific recognition Saliva Orthana provided by the invention to the biochemical analysis of this antibody with in conjunction with epi-position.Contrast immunohistochemical stainings normal to 213 examples and 519 routine tumor tissue sections are analyzed, and knot rectal adenocarcinoma, adenocarcinoma of endometrium and the carcinoma of the pancreas tissue and the cell of the various differentiation degrees of this antibody specific recognition are to corresponding healthy tissues nonrecognition.Animal experiment shows that this antibody has restraining effect to the human colon carcinoma transplanted tumor.Therefore, this antibody can be used for the treatment of colorectal carcinoma.
Description of drawings
Fig. 1 .3P9 monoclonal antibody type is identified.A. detect the antibody classification and the light chain type absorbance value of 3P9 monoclonal antibody; B. typical IgM type immunoglobulin structure synoptic diagram.
Fig. 2 .3P9 Purification of Monoclonal Antibodies and biochemical characteristic.A. through the purifying collection of illustrative plates of prepacked column Sephadex-200 chromatography, peak A, B, C, D, E are respectively the elution peak under the different elution volumes; B. dot blot (Dot blotting) detects antibody purification in the elution peak, and the result shows that antibody mainly concentrates on first peak (A); C. the native SDS-PAGE electrophorogram of antibody purification; D. the reductibility SDS-PAGE electrophoresis result figure of antibody purification.
The association reaction of Fig. 3 .3P9 monoclonal antibody and GenBank AF178428-derived protein GI 7682468 (BSM).
Fig. 4. the sodium periodate oxidation is to the influence of monoclonal antibody 3P9 and GenBank AF178428-derived protein GI 7682468 association reaction.
Fig. 5. neuraminidase is to the influence of monoclonal antibody 3P9 and GenBank AF178428-derived protein GI 7682468 association reaction.
Fig. 6. trypsinase is to the influence of monoclonal antibody 3P9 and GenBank AF178428-derived protein GI 7682468 association reaction.
Fig. 7. monoclonal antibody B72.3 combines with the competition of monoclonal antibody 3P9.
Fig. 8 .3P9 monoclonal antibody identification people ties the rectal adenocarcinoma histocyte.Monoclonal antibody 3P9 and knot rectal adenocarcinoma bonded colour attaching area mainly on epithelioglandular tenuigenin of colorectal cancer and cytolemma, also have fill the air painted simultaneously in lumen of gland; And in normal knot rectal tissue, do not have positive a chrominance signal.Arrow is depicted as the positive coloring site of yellowish brown.
Fig. 9 .3P9 monoclonal antibody identification people adenocarcinoma of endometrium histocyte.Monoclonal antibody 3P9 and adenocarcinoma of endometrium bonded colour attaching area mainly on its epithelioglandular tenuigenin and cytolemma, also have fill the air painted simultaneously in lumen of gland; And in normal endometrial tissue, do not have positive a chrominance signal.Arrow is depicted as the positive coloring site of yellowish brown.
Figure 10 .3P9 monoclonal antibody identification human pancreas cancer histocyte.Monoclonal antibody 3P9 and carcinoma of the pancreas bonded colour attaching area mainly on its epithelioglandular tenuigenin and cytolemma, also have fill the air painted simultaneously in lumen of gland; And in normal pancreatic tissue, do not have positive a chrominance signal.Arrow is depicted as the positive coloring site of yellowish brown.
Figure 11 .3P9 monoclonal antibody suppresses the migration of colon tumor cell.A-G is for adding 100ug/ml respectively, 50ug/ml, 25ug/ml, 12.5ug/ml, 6.3ug/ml 3ug/ml, 0ug/ml serial dilution monoclonal antibody 3P9 handled former generation colorectal carcinoma transplanted tumor cell after HCT-820 hour, the migration of cut district cell all is suppressed, and this restraining effect presents dose-dependently; H is cut district cell growing state before cultivating.
Figure 12 .3P9 monoclonal antibody suppresses human colon tumor's growth.The tumor growth average-volume that the A.sTn+ tumour is measured during the 3P9 Antybody therapy; The tumor growth average-volume that the B.sTn-tumour is measured during the 3P9 Antybody therapy; C. the 30th day the time, each organizes tumor average volume relatively.STn+/3P9 treatment group is significantly less than injection sTn+/PBS group tumor average volume (P＜0.05), and sTn-/3P9 treatment group and injection sTn-/PBS group tumor average volume do not have marked difference (P〉0.05); D. putting to death the knurl of respectively organizing of taking out behind the mouse on the 30th day takes pictures.
Figure 13 .3P9 monoclonal antibody weight chain variable region amino acid sequence and light-chain amino acid sequence.SEQ.ID.NO:1.3P9 monoclonal antibody weight chain variable region amino acid sequence; SEQ.ID.NO:2.3P9 monoclonal antibody light-chain amino acid sequence.
The cell strain 3P9 of the stably express monoclonal antibody that will obtain through colony screening is preserved in the common micro-organisms center (CGMCC of China Committee for Culture Collection of Microorganisms on August 27th, 2008, China, Chaoyang District Beijing Da Tun road), preserving number is CGMCC No.2643.
Embodiment
Hereinafter describe reference example and accompanying drawing in detail the present invention, described embodiment only is intended as illustrative explanation the present invention, rather than intention limits the scope of the invention.Scope of the present invention is specifically limited by accompanying Claim.
The foundation of embodiment one, the strain of 3P9 monoclonal antibody hybridoma cell and the generation of monoclonal antibody
Material: 1. cell SW1116 colon carcinoma cell line, available from U.S. ATCC (American TypeCulture Collection, ATCC No.CCL-233), SP2/0 murine myeloma cell (ATCC No.CRL-1581).2. substratum serum-free DMEM, high sugared DMEM, HAT, the HT substratum is available from Gibco company, foetal calf serum is available from Wuhan Sanli Ltd., Tissue Culture Plate be Coming product 3. reagent polyoxyethylene glycol PEG (MW4000) available from Sigma company, other reagent is homemade analytical pure 4. animal BALB/c mouse available from Institute of Experimental Animals, Chinese Academy of Medical Sciences.5. antibody is identified and is used mouse monoclonal antibody somatotype reagent Sigma ImmunoType Kit antibody subtype detection kit.
Method: 1. mouse immune is with 1 * 10
7/ ml SW1116 cell suspension and each 0.5ml of Fu Shi Freund's complete adjuvant (Sigma) mix emulsification, an abdominal injection 0.2ml/ mouse; 2 week backs are with the mixing and emulsifying suspension second immunisatioies of incomplete freund adjuvant (Sigma), after two weeks with the direct tail vein injection booster immunization of the cell suspension that does not contain adjuvant, the spleen isolated lymphocytes is taken out in the last immunity after 3 days.About 0.2-0.5ml serum free medium DMEM swells it to the spleen injection, punctures the spleen film with a bent injection needle multiple spot again, makes in the lymphocyte clump with the method for pushing and overflows.
2. the foundation of hybridoma cell strain by 1:5 mixes centrifugal with above-mentioned mouse immune splenocyte murine myeloma cell sp2/0, adding 1ml polyoxyethylene glycol PEG merges in 37 ℃ of water-baths, add and to move into the T75 culturing bottle after 15ml contains the high sugared DMEM of 15% foetal calf serum, fused cell is overnight incubation in 37 ℃, 5% CO2gas incubator, add the HAT substratum, making cell concn is 1 * 10
6/ ml divides cell suspension to go into 37 ℃ of two 96 orifice plates (0.2ml/ hole), 5% CO2gas incubator cultivation 3 days, changes liquid with HT substratum half amount, and 1 all backs are with the HT culture medium culturing; Select to have the culture hole of clonal growth after 7-20 days, have or not antibody expression in the detection supernatant, the method (Yan et al., 2003) of utilization enzyme linked immunological absorption (ELISA) filters out the antibody expression positive colony.
3.-the continuous clone hybridization oncocyte of the subclone of positive hybridoma cell employing limiting dilution assay (doubling dilution) filters out the cell strain of stably express antibody for 3 times, and is frozen in liquid nitrogen.
Adopt mouse peritoneal injection hybridoma to collect the method preparation of ascites 4.-ascites antibody prepares, method is referring to document (Mathews et al., 1980; Rammohan et al., 1983).
Result: the cell strain 3P9 that obtains a strain stably express monoclonal antibody through colony screening, described cell strain is preserved in the common micro-organisms center (CGMCC of China Committee for Culture Collection of Microorganisms on August 27th, 2008, China, Chaoyang District Beijing Da Tun road), preserving number is CGMCC No.2643.
Anti-body contg 100-200ng/ml in the cells and supernatant, anti-body contg 2-5mg/ml in the ascites.
Mouse monoclonal antibody somatotype reagent identifies that the monoclonal antibody hypotype is the IgM antibody-like, and light chain of antibody is κ type (Fig. 1), illustrates that this cell strain can stablize high expression level IgM/ κ type monoclonal antibody.
Embodiment two, 3P9 Purification of Monoclonal Antibodies and biochemical characteristic
Material: 3P9 monoclonal antibody ascites is obtained by hybridoma abdominal cavity inoculation BALB/c mouse results ascites; Prepackage chromatography column Sephadex-200, column volume 100ml, the Phamacia product, horseradish peroxidase (HRP) sheep anti mouse IgM antibody is available from Sant Cruz company, the ECL fluorescence detection reagent kit uses AKTA FPLC protein chromatographic system purifying available from Pierce company.
Method: above-mentioned ascites is thawed for 4 ℃, 15, centrifugal 20 minutes of 000g collects supernatant, the degerming of 0.2um film; PH7.2,0.01M PBS balance prepacked column, ascites 5ml goes up sample; PH7.2,0.01M PBS wash-out flow velocity 1ml/ minute, is collected each elution peak; Elution peak sample 10ul point is done dot blot (Dot blotting) and is identified on nitrocellulose filter behind the natural air drying; Albumen biochemical characteristic nativeSDS-PAGE and reductibility SDS-PAGE electrophoretic analysis; Biological activity of albumen is measured with Westernblotting.
Dot blot: 5% skimmed milk room temperature sealing 1 hour, PBST washing three times, again with PBS washing three times, 1:2000 dilution horseradish peroxidase (HRP) sheep anti mouse IgM antibody incubated at room 1 hour, add enhanced chemiluminescence agent (enhanced chemiluminescence, ECL.) colour developing.
The result: ascites is through Sephadex-200 following five peaks of wash-out (Fig. 2 A), and first peak area maximum accounts for 30% total peak area.Dot blot result (Fig. 2 B) shows that the function antibody component mainly is present in first peak, the second peak content pettiness, and all the other are the foreign protein peak.The first peak albumen nativeSDS-PAGE electrophoresis result (Fig. 2 C) of collecting is through Qaulity One software analysis, and purity of protein reaches 95%; Reductibility SDS-PAGE electrophoresis result (Fig. 2 D) is shown as about 75KD protein band.
Embodiment three, 3P9 monoclonal antibody combine with GenBank AF178428-derived protein GI 7682468
Material: the 3P9 monoclonal antibody is obtained through the Sephadex-200 purifying by ascites antibody; Purifying GenBank AF178428-derived protein GI 7682468 (B SM, bovine submaxillary mucin) (Sigma), horseradish peroxidase (HRP) sheep anti mouse IgM antibody is available from Sant Cruz company; 96 hole enzyme-linked immunosorbent assay plates are available from U.S. Coming Costar company.
Method: coating buffer dilution BSM to 50ng/ml, each plate hole adds 100ul, room temperature was spent the night in 2 hours or 4 ℃, get rid of coating buffer, the PBS washing, 2%BSA-PBS sealing 1 hour, the 37 ℃ of incubations of 3P9 monoclonal antibody 1 hour that add 50ul serial dilution purifying, PBS or PBST washing add 50ul horseradish peroxidase (HRP) sheep anti mouse IgM antibody (PBS2,000 times of dilution) 37 ℃ of incubations are 1 hour, PBS washing or PBST washing add 200ul colour developing liquid (prescription: the 0.2M disodium phosphate soln of 5.1ml, the 0.1M citric acid solution of adding 4.9ml, add 10 μ l30% hydrogen peroxide and 4mg O-Phenylene Diamine (OPD)) color development at room temperature 10min, add 20 μ l2M H
2SO
4Termination reaction, 490nm detects absorbance value down.
Result: when being the antibody purification mensuration of 100ng/ml, be obvious logarithm decline (Fig. 3) behind about 0.55, the 2 times of serial dilution of absorption value with the initial concentration.Purifying 3P9 monoclonal antibody shows that with the BSM binding curve association reaction is relevant with antibody concentration, meets antigen-antibody in conjunction with dissociating feature.
Embodiment four, sodium periodate inhibition 3P9 monoclonal antibody combine with GenBank AF178428-derived protein GI 7682468
Material: the 3P9 monoclonal antibody is obtained through the Sephadex-200 purifying by ascites antibody; Purifying GenBank AF178428-derived protein GI 7682468 (BSM, bovine submaxillary mucin) (Sigma), sodium periodate is available from Sigma company, horseradish peroxidase (HRP) sheep anti mouse IgM antibody is available from Sant Cruz company; 96 hole enzyme-linked immunosorbent assay plates are available from U.S. Coming Costar company.
Method: coating buffer (15mM yellow soda ash, the 35mM sodium bicarbonate) dilution BSM to 50ng/ml, each plate hole adds 100ul, room temperature was spent the night in 2 hours or 4 ℃, get rid of coating buffer, the PBS washing, adding 100ul serial dilution sodium periodate room temperature put 20 minutes, abandon that sodium periodate solution adds in the 200ul coating buffer and 5 minutes, the PBS washing, add 2%BSA-PBS sealing 1 hour, add 37 ℃ of incubations of 50ul purifying 3P9 monoclonal antibody (200ng/ml) 1 hour, PBS washing or PBST washing add 50ul horseradish peroxidase (HRP) sheep anti mouse IgM antibody (PBS2,000 times of dilution) 37 ℃ of incubations are 1 hour, PBS washing or PBST washing add 200ul colour developing liquid (prescription: the 0.2M disodium phosphate soln of 5.1ml, the 0.1M citric acid solution of adding 4.9ml, add 10 μ l30% hydrogen peroxide and 4mg O-Phenylene Diamine (OPD)) color development at room temperature 10min, add 20 μ l2M H
2SO
4Termination reaction, 490nm detects absorbance value down.
The result: after sodium periodate was handled, absorbance value increased with sodium periodate dosage and reduces, and shows obvious dose-dependence.Handle absorbance value behind the antigen less than 0.3 (Fig. 4) greater than the 1ug sodium periodate, the oxygenizement that periodates is described has influenced antibody and has combined with BSM.Because periodates can cause the sugar chain structure and the conformational change on Saliva Orthana surface, and do not influence peptide chain structure, so the epi-position structure of 3P9 antibodies Saliva Orthana BSM is sugar chain but not peptide chain.
Embodiment five, neuraminidase inhibition 3P9 monoclonal antibody combine with GenBank AF178428-derived protein GI 7682468
Material: ascites obtains purifying 3P9 monoclonal antibody through the Sephadex-200 purifying; Freeze-drying purifying GenBank AF178428-derived protein GI 7682468 (BSM, bovine submaxillary mucin) (Sigma), neuraminidase is available from Sigma company, horseradish peroxidase (HRP) sheep anti mouse IgM antibody is available from Sant Cruz company; 96 hole enzyme-linked immunosorbent assay plates are available from U.S. Corning Costar company.
Method: coating buffer dilution BSM to 50ng/ml, each plate hole adds 100ul, room temperature was spent the night in 2 hours or 4 ℃, get rid of coating buffer, PBS washing three times, the neuraminic acid enzyme solution (PBS preparation) that adds 100ul1ug/ml and 0.1ug/ml was respectively put 30 minutes for 37 ℃, abandon the neuraminic acid enzyme solution and add 1M EDTA (ethylenediamine tetraacetic acid (EDTA)) solution 200ul room temperature storing 5 minutes, the PBS washing, add 2%BSA-PBS sealing 1 hour, add 37 ℃ of incubations of 50ul purifying 3P9 monoclonal antibody (200ng/ml) 1 hour, PBS washing or PBST washing, add 37 ℃ of incubations of 50ul horseradish peroxidase (HRP) sheep anti mouse IgM antibody (PBS2,000 times of dilution) 1 hour, PBS washing or PBST washing, add 200ul colour developing liquid (prescription: the 0.2M disodium phosphate soln of 5.1ml, add the 0.1M citric acid solution of 4.9ml, add 10 μ l30% hydrogen peroxide and 4mg O-Phenylene Diamine (OPD)) color development at room temperature 10min, add 20 μ l2M H
2SO
4Termination reaction, 490nm detects absorbance value down.
Result: after 10ng and the processing of 100ng neuraminidase, treatment group absorbance value is had obvious reduction (Fig. 5) than control group, further specifying the 3P9 monoclonal antibody, combine epi-position with BSM be the sugar chain part, and relevant with saliva acidifying sugar chain structure, neuraminidase to the change of sugar chain suppressed antibody to the identification of epitope with combine.
The not influence of trypsinize that combines of embodiment six, 3P9 monoclonal antibody and GenBank AF178428-derived protein GI 7682468
Material: the 3P9 monoclonal antibody is obtained through the Sephadex-200 purifying by ascites antibody; Purifying GenBank AF178428-derived protein GI 7682468 (BSM, bovine submaxillary mucin) (Sigma), trypsinase is available from Sigma company, horseradish peroxidase (HRP) sheep anti mouse IgM antibody is available from Sant Cruz company; 96 hole enzyme-linked immunosorbent assay plates are available from Coming Costar company.
Method: coating buffer dilution BSM to 50ng/ml, each plate hole adds 100ul, room temperature was spent the night in 2 hours or 4 ℃, get rid of coating buffer, the PBS washing, add 100ul series gradient trypsinase, put 30 minutes for 37 ℃, abandon trypsin solution and add 1M EDTA solution 200ul room temperature storing 5 minutes, the PBS washing, add 2%BSA-PBS sealing 1 hour, add 37 ℃ of incubations of 50ul purifying 3P9 monoclonal antibody (200ng/ml) 1 hour, PBS washing or PBST washing add 50ul horseradish peroxidase (HRP) sheep anti mouse IgM antibody (PBS2,000 times of dilution) 37 ℃ of incubations are 1 hour, PBS washing or PBST washing add 200ul colour developing liquid (prescription: the 0.2M disodium phosphate soln of 5.1ml, the 0.1M citric acid solution of adding 4.9ml, add 10 μ l30% hydrogen peroxide and 4mg O-Phenylene Diamine (OPD)) color development at room temperature 10min, add 20 μ l2M H
2SO
4Termination reaction, 490nm detects absorbance value down.
Result: after the gradient trypsin treatment, except that each treatment group absorbance value has the small reduction than untreated fish group, the absorbance value considerable change does not appear, each is organized absorption value and all is higher than 0.7, indifference (Fig. 6) between each group, the result shows that trypsinase does not influence 3P9 monoclonal antibody and BSM association reaction to the change of Saliva Orthana peptide chain, proves antibody recognition, and the bonded epitope is non-peptide chain structure.
The knot of embodiment seven, monoclonal antibody B72.3 competition 3P9 monoclonal antibody and GenBank AF178428-derived protein GI 7682468Close
Material: the 3P9 monoclonal antibody is obtained through the Sephadex-200 purifying by ascites antibody; Purifying GenBank AF178428-derived protein GI 7682468 (BSM, bovine submaxillary mucin) (Sigma), monoclonal antibody B72.3 working fluid is available from middle China fir company, horseradish peroxidase (HRP) sheep anti-mouse igg antibody is available from Sigma company; 96 hole enzyme-linked immunosorbent assay plates are available from Coming Costar company.Method: monoclonal antibody B72.3 working fluid 200ul mixes (starting point concentration of 3P9 monoclonal antibody is 600ng/ml) with the 3P9 monoclonal antibody that the gradient amount increases, and each gradient is supplied 500ul with diluent (PBS), and is evenly mixed.Coating buffer dilution BSM to 50ng/ml, each plate hole adds 100ul, room temperature was spent the night in 2 hours or 4 ℃, get rid of coating buffer, the PBS washing, add the above-mentioned serial 3P9 monoclonal antibody mixed solution of 100ul, room temperature was put 1 hour, the PBS washing adds 2%BSA-PBS sealing 1 hour, adds 37 ℃ of incubations of 50ul purifying 3P9 monoclonal antibody (200ng/ml) 1 hour, PBS washing or PBST washing, add 37 ℃ of incubations of 50ul horseradish peroxidase (HRP) sheep anti-mouse igg antibody (PBS2,000 times of dilution) 1 hour, PBS washing or PBST washing, add 200ul colour developing liquid (prescription: the 0.2M disodium phosphate soln of 5.1ml, add the 0.1M citric acid solution of 4.9ml, add 10 μ l30% hydrogen peroxide and 4mg O-Phenylene Diamine (OPD)) color development at room temperature 10min, add 20 μ l2MH
2SO
4Termination reaction, 490nm detects absorbance value down.
Result: monoclonal antibody B72.3 has specificity to combine with purifying BSM; With the increase of monoclonal antibody 3P9 amount, monoclonal antibody B72.3 combines with BSM and obviously reduces (Fig. 7), shows monoclonal antibody 3P9 competition conjugated antigen epi-position, determines that further epitope is s-Tn (sialic acid N-acetylglactoside) sugar chain structure.
Embodiment eight, immunohistochemical analysis 3P9 monoclonal antibody are to the antigenic identification of people's tumor tissues
Material: the many tissue cancers of high-density and health adult tissue's chip (article No.: CC00-08-001) available from Shaanxi Chaoying Biotechnology Co., Ltd..It comprises 500 tissue samples from 495 routine patients, has included 12 kinds of modal cancer types of the mankind, comprises colorectal carcinoma, carcinoma of endometrium, carcinoma of the pancreas, mammary cancer, cancer of the stomach, liver cancer, lung cancer, kidney, skin carcinoma, head and neck cancer, ovarian cancer, spermary cancer, bladder cancer, the cancer of the brain, prostate cancer, thyroid carcinoma etc.Every kind of cancer types comprises about 25 cancerous issue samples and 5 healthy tissues samples.The diameter of each tissue sample is 0.6mm, thickness 5 μ m (details are seen this product description).Other sample comprises human colon carcinoma tissue (52 example), rectum cancer tissue's (50 example), uterine endometrium cancerous tissue (6 example), esophagus cancer (25 example) and corresponding healthy tissues comprise normal people colon (48 example), rectal tissue (50 example), uterine endometrium cancerous tissue (3 example) is taken from molecular weight tumor National Key Laboratory of Tumar Inst of Tumoor Hospital, Chinese Academy of Medical Sciences, the Chinese People's Liberation Army 301 and 306 hospitals, Beijing legal medical expert institute.Horseradish peroxidase (HRP) sheep anti mouse IgM antibody is available from Sant Cruz company; DAB colour developing liquid KIT is available from middle China fir company, and other reagent is available from Beijing chemical reagents corporation.
Method: cryopreserved tissue thaws the back with 4% Paraformaldehyde 96 fixedly 16-24 hour.Experiment material after fixing is put into 70% alcohol, changes 70% alcohol once after 1 hour, through ascending gradient (80%, 90%, 100%) dehydration of alcohol, carries out the routine paraffin wax embedding, the section of 5 μ m thickness.The concrete steps of preparation paraffin organization section are referring to Zhao Zongjiang " histocyte molecules experimental principle and method ", China Traditional Chinese Medicine Publishing House,, first version in 2003.Immunohistochemical staining adopts ordinary method: section is through dimethylbenzene dewaxing, descending gradient (100%, 90%, 80%, 70%, 50%, 30%) alcohol rehydration; The room temperature black out is hatched the interference of removing endogenous peroxydase in 30 minutes in the methyl alcohol that contains 0.3% hydrogen peroxide; PBS flushing three times, each 5 minutes; Place 10mM sodium citrate buffer solution (pH6.0) to boil 10 minutes section, to repair antigen; Allow section naturally cooling in damping fluid, then with PBS flushing three times, each 5 minutes; 5% sheep blood serum (China fir Golden Bridge in Beijing, PBS dilutes sheep blood serum) sealing 1 hour; Discard confining liquid, cover the experimental group section with an anti-diluent that contains the 3P9 monoclonal antibody (dilution of 1:1000 confining liquid), the control group section still covers with 5% sheep blood serum, with containing two underlined anti-(the sheep anti mouse IgM of horseradish peroxidase, Santa Cruz company, the dilution of 1:500 confining liquid) cover experimental group and control group section, 37 hatched 1 hour; PBS flushing three times, each 5 minutes; DAB colouring reagents box with fresh configuration develops the color at last; Microscopically is observed and is developed the color to appropriate level, the reaction of PBS flushing color development stopping; Redye section 1-2 minute with hematoxylin solution; Tap water flushing section 10 minutes; Ascending gradient alcohol (30%, 50%, 70%, 80%, 90%, 100%) dehydration, the transparent back of dimethylbenzene resin mounting; Observe after the section of 37 ℃ of drying in oven and take pictures.
The result: the 3P9 monoclonal antibody is to the positive rate difference very big (table 2) of various cancer types, and combination degree also has very big difference.Wherein the recall rate to adenocarcinoma of colon is the highest, reaches 71.8%, secondly is adenocarcinoma of endometrium (68%), rectal adenocarcinoma (62%), and carcinoma of the pancreas (55.6%), and the strongest to the combination degree of these cancers.
Table 2. people tumor tissues 3P9 Detection of antigen.
1.3P9 monoclonal antibody is tied the antigenic identification of rectal adenocarcinoma histocyte to the people
Monoclonal antibody 3P9 identification, combination knot rectal adenocarcinoma cell and secretory product thereof, present strong yellowish brown color reaction (as shown in Fig. 8 arrow), and healthy tissues does not have color reaction (Fig. 8), instruction book clonal antibody 3P9 can specific recognition, tie the product of rectal adenocarcinoma cell and secreting, expressing, i.e. antigen in conjunction with the people.Immunohistochemical methods interpretation of result to 125 routine clinical adenocarcinoma of colon tissues and healthy tissues shows, monoclonal antibody 3P9 identification human colon adenocarcinoma's susceptibility 71.8%, (51/71), specificity 79.6% (43/54), positive predictive value (PPV) 82.3% (51/62), negative predictive value (NPV) 68.3% (43/63); Immunohistochemical methods interpretation of result to 100 routine clinical rectal adenocarcinoma tissues and healthy tissues shows, the susceptibility 62% of monoclonal antibody 3P9 identification people rectal adenocarcinoma, (31/50), specificity 62% (31/50), positive predictive value (PPV) 62% (31/50), negative predictive value (NPV) 62% (31/50) sees Table 3.
Table 3.3P9 monoclonal antibody detects knot rectal adenocarcinoma, adenocarcinoma of endometrium, the susceptibility of carcinoma of the pancreas and specificity analyses.
PPV: positive predictive value; NPV: negative predictive value;
2.3P9 monoclonal antibody is to the antigenic identification of people's adenocarcinoma of endometrium histocyte
Monoclonal antibody 3P9 identification, in conjunction with uterine endometrium adenocarcinoma cell and secretory product thereof, present strong yellowish brown color reaction (as shown in Fig. 9 arrow), and healthy tissues does not have color reaction (Fig. 9), and instruction book clonal antibody 3P9 can discern, in conjunction with the product of people's endometrial gland cancer cells and secreting, expressing.Immunohistochemical methods interpretation of result to 37 routine clinical endometrial gland cancerous tissues and healthy tissues shows, the susceptibility 68% (17/25) of monoclonal antibody 3P9 identification people adenocarcinoma of endometrium, specificity 100% (12/12), positive predictive value (PPV) 100% (17/17), negative predictive value (NPV) 60% (12/20) sees Table 3.
3.3P9 monoclonal antibody is to the antigenic identification of human pancreas cancer histocyte
Monoclonal antibody 3P9 identification, in conjunction with pancreatic cancer cell and secretory product thereof, present strong yellowish brown color reaction (as shown in Figure 10 arrow), and healthy tissues does not have color reaction (Figure 10), and instruction book clonal antibody 3P9 can discern, in conjunction with the product of human pancreatic cancer cell and secreting, expressing.Immunohistochemical methods interpretation of result to 25 routine clinical carcinoma of the pancreas tissues and healthy tissues shows, the susceptibility 55.6% of monoclonal antibody 3P9 identification human pancreas cancer, (10/18), specificity 100% (7/7), positive predictive value (PPV) 100% (10/10), negative predictive value (NPV) 46.7% (7/15) sees Table 3.
4.3P9 monoclonal antibody is to the relation of the positive rate and the tumour differentiation degree of various cancers
Immunohistochemical methods is the result show, 3P9 has the downward trend with the reduction of tumour differentiation degree to the recall rate of various cancers, and this is particularly evident in adenocarcinoma of endometrium and the carcinoma of the pancreas at adenocarcinoma of colon.But pass through χ
2Check the difference of positive rate between the different differentiation degrees of these cancers, find not significant difference (table 4), instruction book clonal antibody 3P9 does not have dependency to the positive rate of various cancers and the differentiation degree of tumour.
The relation of table 4.3P9 Detection of antigen positive rate and tumour differentiation degree.
(-) do not have positive staining or positive cell number proportion less than 10%; (+) positive cell number proportion is more than or equal to 10% but less than 25%; (++) positive cell number proportion is more than or equal to 25% but less than 50%; (+++) positive cell number proportion is more than or equal to 50%; NS does not have significant difference; UND, unknown differentiation degree.
Embodiment nine, 3P9 monoclonal antibody suppress the migration of tumour cell
Material: colorectal carcinoma transplanted tumor in nude mice HCT-8 is provided by animal housing of Tumar Inst of Tumoor Hospital, Chinese Academy of Medical Sciences, trypsinase, collagenase I is available from Sigma company, and Tissue Culture Plate is Falcon (Becton Dickinson.Labware, Franklin Lakes, NJ, USA) product, cell culture fluid are that DMEM (contains 10% foetal calf serum, penicillin 100U/ml, Streptomycin sulphate 50ug/ml), all the other reagent are available from Beijing chemical company.
Method: the colorectal carcinoma transplanted tumor in nude mice is cut into 1mm
3Fritter prepares former generation colorectal carcinoma transplanted tumor cell HCT-8 with reference to " Zooblast culture medium present technique guide " (Science Press, R.I. Fu Leixieni,, the 4th edition in 2000) method.When the HCT-8 cell grows into individual layer,, abandon nutrient solution with liquid-transfering gun head cut on monolayer cell, PBS washes cell twice, add the DMEM nutrient solution that contains serial dilution monoclonal antibody 3P9, conventional cell cultures 20 hours is observed cut district cell growing state under phase microscope.
The result: compare with cultivating preceding cut (Figure 11 H), monoclonal antibody 3P9 suppresses the migration of HCT-8 colon cancer cell of former generation, and restraining effect presents dose-dependently (Figure 11 A-G).
Embodiment ten, 3P9 monoclonal antibody suppress human colon tumor's growth
Material: 3～4 the week ages, 5～6 the week ages female BALB/c mouse available from Institute of Experimental Animals, Chinese Academy of Medical Sciences; LSC, the LSB cell is so kind as to give (Steven H Itzkowitz et al., 1998) by Steven professor H.Itzkowitz of New York Xi Nai medical college.
Method: in female BALB/c nude mice shoulder back subcutaneous injection 2 * 10 respectively in 3～4 ages in week
6STn positive cell LSC and sTn negative cells LSB get 1mm behind the tumorigenesis
3It is subcutaneous that LSC and LSB tumor tissue are imbedded at 5～6 ages in week female nude mice shoulder backs, observed three days, treat that diameter of tumor reaches 3-5mm, mouse is divided into two groups at random, every group of 10 mouse, handle in contrast with monoclonal antibody 3P9 or PBS respectively: twice intratumor injection 100 μ g/ml3P9 or PBS weekly, so handled 30 days.Measure tumour major diameter and minor axis before the per injection, according to formula: gross tumor volume=width
2Gross tumor volume is calculated in * length * (π/6).
The result: for the sTn+ colorectal carcinoma, 3P9 treatment group tumor growth is slow, and PBS control group gross tumor volume increases soon.The t-check and analysis of measuring gross tumor volume in the 14th, 17,21,24 days show that the gross tumor volume of sTn+/3P9 treatment group and PBS control group have notable difference (n=5, P＜0.05) (Figure 12 A); For the sTn-colorectal carcinoma, and no significant difference between 3P9 treatment group and the control group except that the 28th day observations (n=5, P〉0.05) (Figure 12 B).Put to death the tumor weight result comparison that mouse peels off on the 30th day, sTn+/3P9 treatment group and control group obvious difference (P＜0.05), sTn-/3P9 treatment group and PBS control group no significant difference (P〉0.05) (Figure 12 C, D).Experimentation on animals is the result show, 3P9 antibody has remarkable restraining effect to the growth of mouse sTn positive expression colorectal carcinoma.
Reference
Boland，C.R.，J.A.Roberts，B.Siddiqui，J.Byrd，and?Y.S.Kim，1986，Cancer-associated?colonic?mucin?in?cultured?human?tumor?cells?and?athymic(nude)mouse?xenografts，Cancer?Res.，46(11)：5724-5729.
Bresalier，R.S.，Y.Niv，J.C.Byrd，Q.Y.Duh，N.W.Toribara，R.W.Rockwell，R.Dahiya，and?Y.S.Kim，1991，Mucin?production?by?human?coloniccarcinoma?cells?correlates?with?their?metastatic?potentialin?animal?models?ofcolon?cancer?metastasis，J.Clin.Invest，87(3)：1037-1045.
Brockhausen?I，Yang?J，Dickinson?N，Oqata?S，Itzkowitz?SH，1998，Enzymaticbasisfor?sialyl-Tn?expression?in?human?colon?cancer?cells，GlycoconjJ.，15(6)：595-603.
Cherchi?PL，Capobianco?G，Ambrosini?G，Fadda?GM，Piga?MD，Ruiu?G，Fattorini?F，Dessole?S，2002，Intracystic?evaluation?of?tumor?markers?in?benignand?malignant?ovarian?pathology，Eur?J?Gynaecol?Oncol.，23(2)：163-5.
Coppola?D，2000，Molecular?prognostic?markers?in?pancreatic?cancer，CancerControl，7(5)：421-427
Finkelstein，S.D.，R.Przygodzki，V.E.Pricolo，S.A.Sakallah，P?A.Swalsky，A.Bakker，R.Lanning，K.I.Bland，and?D.L.Cooper，1996b，Prediction?ofBiologic?Aggressiveness?in?Colorectal?Cancer?by?p53/K-ras-2TopographicGenotyping，Mol.Diagn.，1(1)：5-28.
Finkelstein，S.D.，R.Przygodzki，V.E.Pricolo，S.A.Sakallah，P?A.Swalsky，?A.Bakker，R.Lanning，K.I.Bland，and?D.L.Cooper，1996a，Prediction?ofBiologic?Aggressiveness?in?Colorectal?Cancer?by?p53/K-ras-2TopographicGenotyping，Mol.Diagn.，1(1)：5-28.
Hammel，P.，and?T.Soussi，2000，Serum?p53antibody?assay：evaluation?incolorectal?cancer，Rev.Med.Interne，21(2)：167-173.
Hara，A.，M.Saegusa，H.Mitomi，M.Kurihara，K.Ishihara，K.Hotta，and?I.Okayasu，2000，Colonic?mucin-carbohydrate?components?in?colorectal?tumorsand?their?possible?relationship?to?MUC2，p53and?DCC?immunoreactivities，Pathol.Res.Pract.，196(3)：159-166.
Hareyama，H.，Sakuragi，N.，Makinoda，S.，and?Fujimoto，S.1996，Serum?andtissue?measurements?of?CA72-4in?patients?with?endometrial?carcinoma，J?ClinPathol.，49(12)：967-970.
Ho，S.B.，N.W.Toribara，R.S.Bresalier，and?Y.S.Kim，1988，Biochemicaland?other?markers?of?colon?cancer，Gastroenterol.Clin.North?Am.，17(4)：811-836.
Itzkowitz，S.H.，E.J.Bloom，T.S.Lau，and?Y.S.Kim，1992，Mucin?associatedTn?and?sialosyl-Tn?antigen?expression?in?colorectal?polyps，Gut，33(4)：518-523.
Itzkowitz，S.H.，M.Yuan，C.K.Montgomery，T.Kjeldsen，H.K.Takahashi，W.L.Bigbee，and?Y.S.Kim，1989，Expression?of?Tn，sialosyl-Tn，and?T?antigensin?human?colon?cancer，Cancer?Res.，49(1)：197-204.
Kim，Y.S.，1990，Carbohydrate?antigen?expression?in?colorectal?cancer，Semin.Cancer?Biol.，1(3)：189-197.
Kim，Y.S.，1998b，Mucin?glycoproteins?in?colonic?neoplasia，Keio?J.Med.，47(1)：10-18.
Kim，Y.S.，1998a，Mucin?glycoproteins?in?colonic?neoplasia，Keio?J.Med.，47(1)：10-18.
Lassmann，S.，M.Bauer，R.Soong，J.Schreglmann，K.Tabiti，J.Nahrig，R.Ruger，H.Hofler，and?M.Werner，2002，Quantification?of?CK20gene?andprotein?expression?in?colorectal?cancer?by?RT-PCR?and?immunohistochemistryreveals?inter-and?intratumour?heterogeneity，J.Pathol.，198(2)：198-206.Lo?SS，Khoo?US，Cheng?DK，Ng?TY，Wong?LC，Ngan?HY.1999，Role?of?serialtumor?markers?in?the?surveillancefor?recurrence?in?endometrial?cancer，CancerDetect?Prev.，23(5)：397-400.
Mathews，H.L.，M.J.Brunda，and?P?Minden，1980，The?use?of?cellularimmunoadsorbents?to?prepare?antibody?that?distinguishes?between?syngeneicsurface?antigens?on?two?guinea?pig?hepatocarcinomas，J.Immunol.，124(3)：1141-1147.
Ni?XG，Bai?XF，Mao?YL，Shao?YF，Wu?JX，ShanY，Wang?CF，Wang?J，Tian?YT，Liu?Q，Xu?DK，Zhao?P2005，The?clinical?value?of?serum?CEA，CA19-9，andCA242in?the?diagnosis?and?prognosis?of?pancreatic?cancer，Eur?J?Surg?Oncol.，31(2)：164-9.
Rammohan，K.W.，H.F.McFarland，W.J.Bellini，J.Gheuens，and?D.E.McFarlin，1983，Antibody-mediated?modification?of?encephalitis?induced?byhamster?neurotropic?measles?virus，J.Infect.Dis.，147(3)：546-550.
Sanduleanu，S.，and?R.W.Stockbrugger，2003，Screening?for?colorectal?cancer：medical?and?economic?aspects，Scand.J.Gastroenterol.Suppl.，239：73-77.
Winawer，S.J.，2005，Screening?of?colorectal?cancer：progress?and?problems，Recent?Results?Cancer?Res.，166：231-244.
Xiyun?Yan，Dongling?Yang，Yi?Shen，et?al.，2003，A?novel?anti-CD146?monoclonal?antibody，AA98，inhibits?angiogenesis?and?tumor?growth，B?lood，102：184-191
Zhang，Y.L，Z.S.Zhang，B.P?Wu，and?D.Y.Zhou，2002，Early?diagnosis?forcolorectal?cancer?in?China，World?J.Gastroenterol.，8(1)：21-25.
Qin Xiaoguang, 1995, the some problems during tumor markers is used, Chinese journal of medical examination, 18 (4): 197
Wu Daohong, 2004, change of serum C EA, CA19-9, CA724 detect and large bowel cancer differentiation degree, the relation of clinical stages. PLA's medical journal, 29 (1): 69-70
Xu Xiaohong, 1998, four tumour sugar antigens are to the diagnostic sensitivity evaluation of the colorectal carcinoma and the rectum cancer, Clinical Laboratory magazine, 16 (5)
Sequence table
＜110〉Institute of Biophysics, Academia Sinica
＜120〉novel antibody of a kind of human colon tumor of inhibition growth and be used for the treatment of the medicine of colon tumor and the application in the test kit in preparation
<130>IB085931
<160>2
<170>PatentIn?version3.1
<210>1
<211>99
<212>PRT
＜213〉3P9 hybridoma cell strain
<220>
＜221〉3P9 monoclonal antibody weight chain variable region amino acid sequence
<222>(1)..(99)
<223>
<400>1
<210>2
<211>186
<212>PRT
＜213〉3P9 hybridoma cell strain
<220>
＜221〉3P9 monoclonal antibody light-chain amino acid sequence
<222>(1)..(186)
<223>
<400>2
Claims (3)
1. a monoclonal antibody is used for the treatment of the medicine of colorectal carcinoma or the application in the test kit in preparation, and described monoclonal antibody is the hybridoma cell line secretion of CGMCC No.2643 by deposit number.
2. medicine, it is used for the treatment of colorectal carcinoma, comprises hybridoma cell line excretory monoclonal antibody by CGMCC No.2643 as activeconstituents.
3. test kit, it is used for the treatment of colorectal carcinoma, comprises the hybridoma cell line excretory monoclonal antibody by CGMCC No.2643.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008102224177A CN101676301B (en) | 2008-09-16 | 2008-09-16 | Antibody for inhibiting growth of colorectal carcinoma and its use in preparation of medicament and kit |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008102224177A CN101676301B (en) | 2008-09-16 | 2008-09-16 | Antibody for inhibiting growth of colorectal carcinoma and its use in preparation of medicament and kit |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101676301A CN101676301A (en) | 2010-03-24 |
| CN101676301B true CN101676301B (en) | 2011-11-16 |
Family
ID=42029028
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2008102224177A Expired - Fee Related CN101676301B (en) | 2008-09-16 | 2008-09-16 | Antibody for inhibiting growth of colorectal carcinoma and its use in preparation of medicament and kit |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101676301B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101676300B (en) * | 2008-09-16 | 2012-05-02 | 中国科学院生物物理研究所 | Antibody for inhibitting growth of colorectal carcinoma and its use in preparation of diagnostic agent of Colorectal cancer, endometrial carcinoma and pancreatic cancer |
| US11707522B2 (en) * | 2017-10-13 | 2023-07-25 | Boehringer Ingelheim International Gmbh | Human antibodies to Tn antigen |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1958611A (en) * | 2005-10-31 | 2007-05-09 | 中资汉脉（北京）生物技术有限公司 | Mucin antibody in sera, and usage |
| CN101676300A (en) * | 2008-09-16 | 2010-03-24 | 中国科学院生物物理研究所 | Antibody for inhibitting growth of colorectal carcinoma and its use in preparation of diagnostic agent of adenocarcinoma |
-
2008
- 2008-09-16 CN CN2008102224177A patent/CN101676301B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1958611A (en) * | 2005-10-31 | 2007-05-09 | 中资汉脉（北京）生物技术有限公司 | Mucin antibody in sera, and usage |
| CN101676300A (en) * | 2008-09-16 | 2010-03-24 | 中国科学院生物物理研究所 | Antibody for inhibitting growth of colorectal carcinoma and its use in preparation of diagnostic agent of adenocarcinoma |
Non-Patent Citations (1)
| Title |
|---|
| 黄卓垣等.结肠肿瘤性病变单克隆抗体MC3的表达及其与异型粘液分泌的关系.《癌症》.1991,第10卷(第4期),302-304. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101676301A (en) | 2010-03-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Weber et al. | The use of a combination of galectin-3 and thyroid peroxidase for the diagnosis and prognosis of thyroid cancer | |
| CN103476428B (en) | For diagnosing blood markers thing and the monoclonal antibody thereof of epitheliogenic cancerg | |
| CN101676300B (en) | Antibody for inhibitting growth of colorectal carcinoma and its use in preparation of diagnostic agent of Colorectal cancer, endometrial carcinoma and pancreatic cancer | |
| RU2319969C2 (en) | Method for diagnosing hepatocellular carcinoma cases | |
| Silsirivanit et al. | A novel serum carbohydrate marker on mucin 5AC: values for diagnostic and prognostic indicators for cholangiocarcinoma | |
| KR102262720B1 (en) | Anti-muc1 antibody or antigen-binding fragment of same, and use thereof | |
| Davidson et al. | Carbohydrate antigen expression in primary tumors, metastatic lesions, and serous effusions from patients diagnosed with epithelial ovarian carcinoma: evidence of up-regulated Tn and Sialyl Tn antigen expression in effusions | |
| KR20100015438A (en) | He4 monoclonal antibodies and methods for their use | |
| EP1678503B1 (en) | Specific method for cancer detection | |
| KR20160039295A (en) | Cancer detection method | |
| CN104471404B (en) | The detection method of cancer | |
| JPWO2009028417A1 (en) | Gynecologic cancer detection method | |
| US6835549B2 (en) | Immunoassay method for the diagnosis of gastric intestinal metaplasia associated with gastric carcinoma | |
| CN104471403B (en) | The detection method of cancer | |
| Lee et al. | Molecular identity of a pan cancer marker, CA215 | |
| US20080118935A1 (en) | Methods and compositions for diagnosing neoplastic disease | |
| Yu et al. | Relationship between expression of CD105 and growth factors in malignant tumors of gastrointestinal tract and its significance | |
| CN101290318B (en) | ELISA reagent kit for diagnosing liver cancer | |
| EP1718676B1 (en) | Anti-clusterin oligoclonal antibodies for diagnosis and prediction of the aggressiveness of tumours, diagnostic method and related kits | |
| CN101676301B (en) | Antibody for inhibiting growth of colorectal carcinoma and its use in preparation of medicament and kit | |
| CN103923212A (en) | EHD2 antibody and application of EHD2 antibody to preparation of immunohistochemical detection reagent for breast cancer | |
| KR20090040118A (en) | A kit for diagnosis of breast cancer using herceptin, a composition comprising herceptin and a method for detecting herceptin-sensitive her2 over expressed cell using the same | |
| US20140093892A1 (en) | Marker comprising anti-ck8/18 complex autoantibody and its use for diagnosing cancer | |
| CN110684108B (en) | anti-MG 7-Ag monoclonal antibody (CEA37) and application thereof | |
| CN106928352B (en) | Monoclonal antibody of anti-PSG 3 protein, hybridoma cell strain and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20111116 Termination date: 20210916 |